References
- Schimmel J, Amioka E, Rockhill K, Haynes CM, Black JC, Dart RC, Iwanicki JL. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study. Addiction. 2021;116(1):176–81. doi:https://doi.org/10.1111/add.15082.
- Goldin D, Salani D, McKay M. Kratom: Implications for health care providers. J Psychosoc Nurs Ment Health Serv. 2019;57(12):15–20. doi:https://doi.org/10.3928/02793695-20191112-03.
- Anwar M, Law R, Schier J. Notes from the field : kratom (Mitragyna speciosa) exposures reported to poison centers - United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65(29):748–9. doi:https://doi.org/10.15585/mmwr.mm6529a4.
- Kuehn B. Kratom-related deaths. JAMA. 2019;321(20):1966. doi:https://doi.org/10.1001/jama.2019.6339.
- Grundmann O. Patterns of Kratom use and health impact in the US-results from an online survey. Drug Alcohol Depend. 2017;176:63–70. doi:https://doi.org/10.1016/j.drugalcdep.2017.03.007.
- Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130(1):127–38. doi:https://doi.org/10.1007/s00414-015-1279-y.
- Diversion Control Division D. KRATOM (Mitragyna Speciosa Korth) (Street Names: Thang, Kakuam, Thom, Ketum, Biak); 2019.
- Hassan Z, Muzaimi M, Navaratnam V, Yusoff NHM, Suhaimi FW, Vadivelu R, Vicknasingam BK, Amato D, von Hörsten S, Ismail NIW, et al. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev. 2013;37(2):138–51. doi:https://doi.org/10.1016/j.neubiorev.2012.11.012.
- White CM. Pharmacologic and clinical assessment of kratom. Am J Health Syst Pharm. 2018;75(5):261–7. doi:https://doi.org/10.2146/ajhp161035.
- Prozialeck WC, Avery BA, Boyer EW, Grundmann O, Henningfield JE, Kruegel AC, McMahon LR, McCurdy CR, Swogger MT, Veltri CA, et al. Kratom policy: the challenge of balancing therapeutic potential with public safety. Int J Drug Policy. 2019;70:70–7. doi:https://doi.org/10.1016/j.drugpo.2019.05.003.
- Federal Register : Withdrawal of notice of intent to temporarily place mitragynine and 7-hydroxymitragynine into schedule I. [accessed 2021 Jun 5]. https://www.federalregister.gov/documents/2016/10/13/2016-24659/withdrawal-of-notice-of-intent-to-temporarily-place-mitragynine-and-7-hydroxymitragynine-into.
- The Average Price of Kratom Online & Locally • Golden Monk. [accessed 2021 Jan 17]. https://goldenmonk.com/buy-kratom/average-kratom-cost-online-local/.
- Unauthorized kratom products seized from Culture Rising store in Milton, ON - Recalls and safety alerts. [accessed 2021 Jun 5]. https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/63906a-eng.php.
- Fu H, Cid F, Dworkin N, Cocores J, Shore G. Screening and identification of mitragynine and 7-hydroxymitragynine in human urine by LC-MS/MS. Chromatography. 2015;2(2):253–64. doi:https://doi.org/10.3390/chromatography2020253.
- Le D, Goggin MM, Janis GC. Analysis of mitragynine and metabolites in human urine for detecting the use of the psychoactive plant kratom. J Anal Toxicol. 2012;36(9):616–25. doi:https://doi.org/10.1093/jat/bks073.
- Gryczynski J, Schwartz RP, Mitchell SG, O’Grady KE, Ondersma SJ. Hair drug testing results and self-reported drug use among primary care patients with moderate-risk illicit drug use. Drug Alcohol Depend. 2014;141:44–50. doi:https://doi.org/10.1016/j.drugalcdep.2014.05.001.
- Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2016; 2018. [accessed 2019 Jun 25]. https://www.cdc.gov/nchs/data/databriefs/db329_tables-508.pdf#3.
- Rosenbaum CD, Carreiro SP, Babu KM. Here Today, Gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol. 2012;8(1):15–32. doi:https://doi.org/10.1007/s13181-011-0202-2.
- Kratom strains | red vein, white or green | Kratomgardens.com. [accessed 2021 Jan 13]. https://www.kratomgardens.com/en/kratom-strains.
- Where To Buy Kratom Near Me: Dangers of Buying Locally - SF Weekly. [accessed 2021 Jan 17]. https://www.sfweekly.com/sponsored/where-to-buy-kratom-near-me-dangers-of-buying-locally/.
- Braley C, Hondrogiannis EM. Differentiation of commercially available kratom by purported country of origin using inductively coupled plasma-mass spectrometry. J Forensic Sci. 2020;65(2):428–37. doi:https://doi.org/10.1111/1556-4029.14201.
- Tanguay P. Kratom in Thailand: decriminalisation and community control? Series on legislative reform of drug policies No. 13, Transnational Institute. International Drug Policy Consortium (IPDC), LD Amsterdam The Netherlands. [accessed 2020 Dec 6]. https://www.tni.org/en/briefing/kratom-thailand-decriminalisation-and-community-control.
- Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 2008;103(6):1048–50. doi:https://doi.org/10.1111/j.1360-0443.2008.02209.x.
- Singh D, Narayanan S, Vicknasingam B. Traditional and non-traditional uses of Mitragynine (Kratom): a survey of the literature. Brain Res Bull. 2016;126(1):41–6. doi:https://doi.org/10.1016/j.brainresbull.2016.05.004.
- Singh D, Narayanan S, Müller CP, Swogger MT, Chear NJY, Dzulkapli EB, Yusoff NSM, Ramachandram DS, León F, McCurdy CR, et al. Motives for using Kratom (Mitragyna speciosa Korth.) among regular users in Malaysia. J Ethnopharmacol. 2019;233:34–40. doi:https://doi.org/10.1016/j.jep.2018.12.038.
- Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE. Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend. 2019;202:24–32. doi:https://doi.org/10.1016/j.drugalcdep.2019.05.005.
- Henningfield JE, Fant RV, Wang DW. The abuse potential of Kratom according the 8 factors of the controlled substances act: implications for regulation and research. Psychopharmacology (Berl)). 2018;235(2):573–89. doi:https://doi.org/10.1007/s00213-017-4813-4.
- Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. 2020;208:107849. doi:https://doi.org/10.1016/j.drugalcdep.2020.107849.
- Boyer EW, Babu KM, Macalino GE, Compton W. Self-treatment of opioid withdrawal with a dietary supplement, Kratom. Am J Addict. 2007;16(5):352–6. doi:https://doi.org/10.1080/10550490701525368.
- Müller E, Hillemacher T, Müller CP. Kratom instrumentalization for severe pain self-treatment resulting in addiction - a case report of acute and chronic subjective effects. Heliyon. 2020;6(7)e04507. doi:https://doi.org/10.1016/j.heliyon.2020.:.
- Wright ME, Ginsberg C, Parkison AM, Dubose M, Shores E. Outcomes of mothers and newborns to prenatal exposure to Kratom: a systematic review. J Perinatol. 2021;41(6):1236–43. doi:https://doi.org/10.1038/s41372-021-00952-8.
- Kruegel AC, Gassaway MM, Kapoor A, Váradi A, Majumdar S, Filizola M, Javitch JA, Sames D. Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc. 2016;138(21):6754–64. doi:https://doi.org/10.1021/jacs.6b00360.
- Utar Z, Majid MIA, Adenan MI, Jamil MFA, Lan TM. Mitragynine inhibits the COX-2 mRNA expression and prostaglandin E₂ production induced by lipopolysaccharide in RAW264.7 macrophage cells . J Ethnopharmacol. 2011;136(1):75–82. doi:https://doi.org/10.1016/j.jep.2011.04.011.
- Johnson LE, Balyan L, Magdalany A, Saeed F, Salinas R, Wallace S, Veltri CA, Swogger MT, Walsh Z, Grundmann O, et al. The potential for kratom as an antidepressant and antipsychotic. Yale J Biol Med. 2020;93(2):283–9. [accessed 2020 Dec 10]. https://pubmed-ncbi-nlm-nih-gov.ezaccess.libraries.psu.edu/32607089/.
- LaBryer L, Sharma R, Chaudhari KS, Talsania M, Scofield RH. Kratom, an emerging drug of abuse, raises prolactin and causes secondary hypogonadism: case report. J Investig Med High Impact Case Rep. 2018;6:3. doi:https://doi.org/10.1177/2324709618765022.
- Fluyau D, Revadigar N. Biochemical benefits, diagnosis, and clinical risks evaluation of kratom. Front Psychiatry. 2017;8:62. doi:https://doi.org/10.3389/fpsyt.2017.00062.
- Bone C, Gelberg L, Vahidi M, Leake B, Yacenda-Murphy J, Andersen RM. Under-reporting of risky drug use among primary care patients in federally qualified health centers. J Addict Med. 2016;10(6):387–94. doi:https://doi.org/10.1097/ADM.0000000000000246.
- Lanzarotta A, Thatcher MD, Lorenz LM, Batson JCS. Detection of mitragynine in Mitragyna speciosa (Kratom) using surface-enhanced Raman spectroscopy with handheld devices. J Forensic Sci. 2020;65(5):1443–9. doi:https://doi.org/10.1111/1556-4029.14457.
- Singh D, Müller CP, Vicknasingam BK, Mansor SM. Social functioning of Kratom (Mitragyna speciosa) users in Malaysia. J Psychoactive Drugs. 2015;47(2):125–31. doi:https://doi.org/10.1080/02791072.2015.1012610.
- Singh D, Müller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:132–7. doi:https://doi.org/10.1016/j.drugalcdep.2014.03.017.
- Veltri C, Grundmann O. Current perspectives on the impact of Kratom use. Subst Abuse Rehabil. 2019;10:23–31. Volumedoi:https://doi.org/10.2147/sar.s164261.
- Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, Boyer EW. Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. J Med Toxicol. 2016;12(4):341–9. doi:https://doi.org/10.1007/s13181-016-0588-y.
- Ellis CR, Racz R, Kruhlak NL, Kim MT, Zakharov AV, Southall N, Hawkins EG, Burkhart K, Strauss DG, Stavitskaya L, et al. Evaluating kratom alkaloids using PHASE. PLoS One. 2020;15(3):e0229646. doi:https://doi.org/10.1371/journal.pone.0229646.
- White CM. Pharmacologic and clinical assessment of kratom: an update. Am J Health Syst Pharm. 2019;76(23):1915–25. doi:https://doi.org/10.1093/ajhp/zxz221.
- Osborne CS, Overstreet AN, Rockey DC, Schreiner AD. Drug-induced liver injury caused by kratom use as an alternative pain treatment amid an ongoing opioid epidemic. J Investig Med High Impact Case Rep. 2019;7. doi:https://doi.org/10.1177/2324709619826167.
- Raehal KM, Bohn LM. β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handb Exp Pharmacol. 2014;219:427–43. doi:https://doi.org/10.1007/978-3-642-41199-1_22.
- McWhirter L, Morris S. A case report of inpatient detoxification after kratom (Mitragyna speciosa) dependence. Eur Addict Res. 2010;16(4):229–31. doi:https://doi.org/10.1159/000320288.
- Galbis-Reig D. A case report of kratom addiction and withdrawal. Wis Med J. 2016;115(1):49–52. [accessed 2020 Dec 23]. http://europepmc.org/article/med/27057581.
- Diep J, Chin DT, Gupta S, Syed F, Xiong M, Cheng J. Kratom, an emerging drug of abuse: a case report of overdose and management of withdrawal. A&A Pract. 2018;10(8):192–4. doi:https://doi.org/10.1213/xaa.0000000000000658.
- Schmid CL, Kennedy NM, Ross NC, Lovell KM, Yue Z, Morgenweck J, Cameron MD, Bannister TD, Bohn LM. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell. 2017;171(5):1165–e13-1175.e13. doi:https://doi.org/10.1016/j.cell.2017.10.035.